AlzeCure announces positive data from clinical study with ACD856
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received positive results from the first clinical study with ACD856, aiming to evaluate half-life in humans. ACD856 is currently under development for e.g. Alzheimer’s disease.The results demonstrate that ACD856, the lead drug candidate within the company's NeuroRestore platform, has a good pharmacokinetic profile with a significantly